来那度胺治疗的B细胞非霍奇金淋巴瘤患者的静脉血栓栓塞:系统综述与荟萃分析
该系统综述与荟萃分析检索了截至2017年2月的多个数据库,纳入28项前瞻性研究,评估来那度胺方案治疗B细胞非霍奇金淋巴瘤(NHL)的静脉血栓栓塞(VTE)发生率。每100患者周期VTE总发生率为0.77(95%CI 0.48-1.12;I²=67%),与多发性骨髓瘤相似;来那度胺联合生物制剂发生率最低(0.49,95%CI 0.17-0.97;I²=59%)。
要点
- B细胞NHL患者来那度胺治疗每100患者周期VTE发生率为0.77(95%CI 0.48-1.12;I²=67%)。
- 单药来那度胺VTE发生率为1.09(95%CI 0.49-1.94;I²=76%)。
- 来那度胺联合生物制剂VTE发生率最低,为0.49(95%CI 0.17-0.97;I²=59%)。
核心结论
- 临床试验中B细胞NHL患者接受来那度胺治疗的VTE发生率与多发性骨髓瘤患者相似。
- 与单药来那度胺或联合化疗相比,来那度胺联合生物制剂的VTE发生率似乎最低。
研究设计与样本
- 系统文献检索Ovid MEDLINE(1946年至2017年2月)、Ovid EMBASE(1974年至2017年2月)、Cochrane图书馆(Wiley)和Web of Science核心合集,纳入评估含来那度胺方案治疗B细胞NHL的前瞻性研究,要求充分报告患者特征、总治疗周期数和包括VTE发生率的安全性数据。
- 共检索到1719条引文,最终纳入28篇文章。
- 主要结局为每100患者周期的VTE事件,采用随机效应模型进行荟萃分析。
- 方案已在PROSPERO注册,注册号为CRD42017056042。
主要发现
- 所有接受来那度胺治疗的B细胞NHL患者,每100患者周期VTE发生率为0.77(95%CI 0.48-1.12;I²=67%)。
- 单药来那度胺的VTE发生率为每100患者周期1.09次事件(95%CI 0.49-1.94;I²=76%)。
- 来那度胺联合生物制剂的VTE发生率为0.49(95%CI 0.17-0.97;I²=59%)。
- 来那度胺联合化疗的VTE发生率为0.89(95%CI 0.39-1.60;I²=57%)。
局限性
- 异质性I²=67%。
- 单药来那度胺亚组异质性I²=76%。
- 来那度胺联合生物制剂亚组异质性I²=59%。
- 来那度胺联合化疗亚组异质性I²=57%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lenalidomide is associated with increased risk of thromboembolism (VTE) in patients with multiple myeloma. This risk has not previously been defined in B-cell non-Hodgkin lymphoma (NHL), for which lenalidomide is also an active agent. We conducted a systematic literature search in Ovid MEDLINE (1946 to February 2017), Ovid EMBASE (1974 to February 2017), The Cochrane Library (Wiley), and Web of Science Core Collection for prospective studies evaluating lenalidomide-containing regimens in B-cell NHL with adequate reporting of patient characteristics, total cycles received, and safety data including VTE rates. The primary outcome was VTE events per 100 patient-cycles by meta-analysis using random-effects models. Our literature search identified 1719 citations; 28 articles were included. For all patients with B-cell NHL receiving lenalidomide, the rate of VTE per 100 patient-cycles was 0.77 (95% confidence interval [CI], 0.48-1.12; I2, 67%). The rate for single-agent lenalidomide was 1.09 events per 100 patient-cycles (95% CI, 0.49-1.94; I2, 76%), the rate for lenalidomide plus biologics was 0.49 (95% CI, 0.17-0.97; I2, 59%), and the rate for lenalidomide plus chemotherapy was 0.89 (95% CI, 0.39-1.60; I2, 57%). Rate of VTE events in B-cell NHL patients treated with lenalidomide in clinical trials is similar to the rate in multiple myeloma. The VTE rate appears to be lowest for lenalidomide combined with a biologic compared with single-agent lenalidomide or its combination with chemotherapy. This protocol was registered at www.crd.york.ac.uk/prospero/ as #CRD42017056042.
引用
- Yamshon S, Christos PJ, Demetres M, et al. Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis. Blood Adv. 2018. PMID: 29934343. doi:10.1182/bloodadvances.2018016683
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。